Short answer
Biohaven Ltd. (BHVN) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$173M
- −8.2% YoY · +12.5% QoQ
- EPS (diluted)
- −$1.63
- −3.8% YoY · +16.0% QoQ
Source: XBRL data from the Biohaven Ltd. (BHVN) Q3 2025 10-Q on SEC EDGAR. USD.
Biohaven Ltd. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New financial risk: $250M senior secured notes issued Apr 28, 2025 under Note Purchase Agreement with potential $350M additional tranches, contingent on FDA approval
- Updated financial risk: obligation to pay 6.25% royalty on global net sales of troriluzole plus milestone payments up to 35% of Funded Amount upon FDA/EMA approval
- Regulatory/compliance risk: FDA approval of troriluzole triggers milestone payments and conditions for additional note purchases by lenders
- Operational risk: restrictive covenants limit Biohaven’s ability to incur debt, make acquisitions, pay dividends, or repurchase stock, impacting strategic flexibility
- Financial risk: default may trigger Put Option requiring note repurchase, risking foreclosure on cash, equity interests, and troriluzole assets affecting liquidity and operations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Biohaven Ltd. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.